ABVC Historical Income Statement

ABVC Stock  USD 0.55  0.01  1.79%   
Historical analysis of ABVC Biopharma income statement accounts such as Selling General Administrative of 5 M, Total Revenue of 157.4 K or Other Operating Expenses of 4.2 M can show how well ABVC Biopharma performed in making a profits. Evaluating ABVC Biopharma income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of ABVC Biopharma's future profits or losses.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Financial Statement Analysis is much more than just reviewing and examining ABVC Biopharma latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether ABVC Biopharma is a good buy for the upcoming year.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ABVC Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
For information on how to trade ABVC Stock refer to our How to Trade ABVC Stock guide.

About ABVC Income Statement Analysis

ABVC Biopharma Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to ABVC Biopharma shareholders. The income statement also shows ABVC investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

ABVC Biopharma Income Statement Chart

At present, ABVC Biopharma's Total Revenue is projected to increase significantly based on the last few years of reporting. The current year's Cost Of Revenue is expected to grow to about 347.1 K, whereas Selling General Administrative is forecasted to decline to about 5 M.

Total Revenue

Total revenue comprises all receipts ABVC Biopharma generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of ABVC Biopharma. It is also known as ABVC Biopharma overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Cost Of Revenue

Cost of Revenue is found on ABVC Biopharma income statement and represents the costs associated with goods and services ABVC Biopharma provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.
Most accounts from ABVC Biopharma's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into ABVC Biopharma current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ABVC Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
For information on how to trade ABVC Stock refer to our How to Trade ABVC Stock guide.At present, ABVC Biopharma's Total Revenue is projected to increase significantly based on the last few years of reporting. The current year's Cost Of Revenue is expected to grow to about 347.1 K, whereas Selling General Administrative is forecasted to decline to about 5 M.
 2021 2022 2023 2024 (projected)
Other Operating Expenses11.7M16.1M8.4M4.2M
Total Revenue355.8K969.8K152.4K157.4K

ABVC Biopharma income statement Correlations

0.250.080.24-0.39-0.39-0.390.80.23-0.48-0.46-0.27-0.420.120.18-0.51-0.51-0.480.17-1.00.80.18-0.42
0.250.750.98-0.98-0.97-0.970.420.98-0.89-0.930.6-0.03-0.040.54-0.58-0.93-0.50.76-0.240.68-0.7-0.82
0.080.750.8-0.76-0.75-0.740.310.8-0.68-0.710.90.00.470.4-0.65-0.7-0.520.5-0.070.53-0.58-0.36
0.240.980.8-0.98-0.97-0.970.451.0-0.91-0.940.63-0.070.020.51-0.65-0.93-0.550.76-0.230.68-0.67-0.75
-0.39-0.98-0.76-0.981.01.0-0.56-0.980.950.97-0.540.130.01-0.530.680.980.59-0.770.36-0.780.610.82
-0.39-0.97-0.75-0.971.01.0-0.57-0.970.940.97-0.530.110.01-0.50.670.970.58-0.770.37-0.790.60.82
-0.39-0.97-0.74-0.971.01.0-0.57-0.970.940.97-0.520.110.02-0.50.670.970.57-0.770.37-0.790.60.82
0.80.420.310.45-0.56-0.57-0.570.44-0.63-0.64-0.12-0.39-0.070.38-0.6-0.68-0.520.43-0.790.890.17-0.42
0.230.980.81.0-0.98-0.97-0.970.44-0.91-0.940.64-0.070.020.51-0.64-0.92-0.550.76-0.220.68-0.68-0.75
-0.48-0.89-0.68-0.910.950.940.94-0.63-0.910.99-0.430.44-0.01-0.50.790.980.77-0.660.46-0.80.540.74
-0.46-0.93-0.71-0.940.970.970.97-0.64-0.940.99-0.460.340.01-0.530.780.990.73-0.710.44-0.810.570.77
-0.270.60.90.63-0.54-0.53-0.52-0.120.64-0.43-0.460.180.530.25-0.41-0.43-0.310.320.280.15-0.69-0.19
-0.42-0.030.0-0.070.130.110.11-0.39-0.070.440.340.18-0.05-0.050.540.290.740.130.42-0.3-0.030.0
0.12-0.040.470.020.010.010.02-0.070.02-0.010.010.53-0.05-0.11-0.290.05-0.31-0.2-0.130.02-0.080.3
0.180.540.40.51-0.53-0.5-0.50.380.51-0.5-0.530.25-0.05-0.11-0.43-0.56-0.320.61-0.210.44-0.3-0.53
-0.51-0.58-0.65-0.650.680.670.67-0.6-0.640.790.78-0.410.54-0.29-0.430.770.92-0.420.52-0.650.490.44
-0.51-0.93-0.7-0.930.980.970.97-0.68-0.920.980.99-0.430.290.05-0.560.770.68-0.720.49-0.860.540.81
-0.48-0.5-0.52-0.550.590.580.57-0.52-0.550.770.73-0.310.74-0.31-0.320.920.68-0.310.49-0.540.440.34
0.170.760.50.76-0.77-0.77-0.770.430.76-0.66-0.710.320.13-0.20.61-0.42-0.72-0.31-0.150.54-0.37-0.83
-1.0-0.24-0.07-0.230.360.370.37-0.79-0.220.460.440.280.42-0.13-0.210.520.490.49-0.15-0.78-0.170.39
0.80.680.530.68-0.78-0.79-0.790.890.68-0.8-0.810.15-0.30.020.44-0.65-0.86-0.540.54-0.78-0.12-0.66
0.18-0.7-0.58-0.670.610.60.60.17-0.680.540.57-0.69-0.03-0.08-0.30.490.540.44-0.37-0.17-0.120.5
-0.42-0.82-0.36-0.750.820.820.82-0.42-0.750.740.77-0.190.00.3-0.530.440.810.34-0.830.39-0.660.5
Click cells to compare fundamentals

ABVC Biopharma Account Relationship Matchups

ABVC Biopharma income statement Accounts

201920202021202220232024 (projected)
Interest Expense482.0K405.0K227.2K294.0K2.5M2.6M
Selling General Administrative3.1M8.4M11.1M13.1M7.0M5.0M
Total Revenue701.7K483.0K355.8K969.8K152.4K157.4K
Other Operating Expenses4.2M9.0M11.7M16.1M8.4M4.2M
Operating Income(3.5M)(8.5M)(11.3M)(15.1M)(8.2M)(7.8M)
Ebit(3.5M)(8.2M)(11.1M)(14.8M)(8.2M)(7.8M)
Ebitda(3.3M)(8.2M)(11.1M)(14.8M)(8.2M)(7.8M)
Cost Of Revenue20.1K18.7K5.1K286.4K330.6K347.1K
Total Operating Expenses4.1M9.0M11.7M15.8M8.0M4.2M
Income Before Tax(4.0M)(10.8M)(11.2M)(15.5M)(10.7M)(10.1M)
Net Income(3.9M)(10.6M)(12.0M)(16.3M)(10.5M)(10.0M)
Gross Profit681.6K464.3K350.7K683.4K(178.1K)(169.2K)
Total Other Income Expense Net(551.5K)(2.3M)134.2K(400.2K)(2.4M)(2.3M)
Depreciation And Amortization195.3K37.1K12.0K23.8K28.5K40.3K
Income Tax Expense(77.0K)(220.4K)825.0K797.8K256.0K268.8K
Net Income From Continuing Ops(3.9M)(10.6M)(12.0M)(16.3M)(10.9M)(11.5M)
Research Development1.0M549.7K1.0M2.7M1.1M1.0M
Net Income Applicable To Common Shares(3.6M)(9.8M)(12.8M)(16.4M)(14.8M)(14.0M)
Tax Provision(77.0K)(220.4K)825.0K797.8K256.0K217.9K
Net Interest Income(458.7K)(334.0K)(184.0K)(106.2K)(2.3M)(2.2M)
Interest Income23.3K71.0K43.2K187.8K185.5K194.8K
Minority Interest26.1K(776.3K)(803.0K)(110.9K)394.6K414.4K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether ABVC Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ABVC Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Abvc Biopharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Abvc Biopharma Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ABVC Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
For information on how to trade ABVC Stock refer to our How to Trade ABVC Stock guide.
You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ABVC Biopharma. If investors know ABVC will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ABVC Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.66)
Revenue Per Share
0.017
Quarterly Revenue Growth
18.175
Return On Assets
(0.45)
Return On Equity
(3.20)
The market value of ABVC Biopharma is measured differently than its book value, which is the value of ABVC that is recorded on the company's balance sheet. Investors also form their own opinion of ABVC Biopharma's value that differs from its market value or its book value, called intrinsic value, which is ABVC Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ABVC Biopharma's market value can be influenced by many factors that don't directly affect ABVC Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ABVC Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if ABVC Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ABVC Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.